PubMed
Cartilage bioregulatory peptide in osteoarthritis models (preclinical review)
Khavinson VK, et al. Adv Gerontol. 2014
Compare
Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.
Last reviewed . By the PeptIQ team.
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 70% · Mixed 12% · Unfavorable overall 18%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.025–5 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 65% said they felt similar to their last entry, 38% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 24 days · Based on 419 repeat reporters
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 50% · Mixed 40% · Unfavorable overall 10%
Benefits users selected when logging a favorable or mixed check-in.
Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Median bucket: 0.4–0.6 mg · Most common: 0.4–0.6 mg
Reports span 0.025–3 mg
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Among repeat reporters, 60% said they felt similar to their last entry, 42% more positive, and 20% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 31 days · Based on 336 repeat reporters
Published sources linked on the Cartalax and Thymosin Alpha-1 wiki pages.
PubMed
Khavinson VK, et al. Adv Gerontol. 2014
PubMed
Khavinson VK. Biogerontology. 2009
PubMed
Romani L, Moretti S, Fallarino F, et al. Expert Opin Biol Ther. 2020
PubMed
Tuthill C, Rios I, McBeath R. Ann N Y Acad Sci. 2010
PubMed
Garaci E, Pica F, Serafino A, et al. Ann N Y Acad Sci. 2014
ClinicalTrials.gov
ClinicalTrials.gov. Clinical trial registry. 2024
PubMed
Naylor PH, Mutchnick MG. Journal of viral hepatitis. 2018
PubMed
Al-Mahtab M, Bazinet M, Vaillant A. PloS one. 2016